Raltegravir Receives Official FDA Authorization, Becomes First U.S. Drug Approved for New Crown Treatment

U.S. Food and Drug Administration approves Radicevir for the treatment of neo-crown hospitalized patients.

On Oct. 22, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ antiviral drug raltegravir for the treatment of patients hospitalized with new crowns, making it the first officially approved neo-crown treatment in the U.S. The drug will be sold under the brand name Veklury for the treatment of patients over the age of 12.

Radecevir will be sold under the trade name Veklury for use in U.S. patients 12 years of age and older who are hospitalized for a new coronary. According to Gilead, it is now available to meet the immediate needs of U.S. inpatients and global demand at the end of October.

Gilead’s shares rose more than 5% after hours on the positive news.

It’s worth noting that WHO had previously said that raltegravir and others had little impact on improving the mortality rate of patients hospitalized with new coronary pneumonia.

Gilead Sciences on Oct. 8 announced phase 3 clinical data for raltegravir from a biologically randomized, double-blind, placebo-controlled phase 3 study led by the National Institute of Allergy and Infectious Diseases (NIAID) covering about 1,060 hospitalized patients worldwide. The data showed that hospitalized patients treated with raltegravir recovered an average of five days faster, compared to seven days faster for patients with serious illnesses, which accounted for 85 percent of the study population.